Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Brain Neoplasms 7Glioblastoma 6Squamous Cell Carcinoma of Head and Neck 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Gliosarcoma 5Polycythemia Vera 4Meningioma 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Acute 4Head and Neck Neoplasms 4Neoplasms 3Leukemia 3Laryngeal Neoplasms 3Glioma 3Thrombocythemia, Essential 2Primary Myelofibrosis 2Pharyngeal Neoplasms 2Paranasal Sinus Neoplasms 2Myelodysplastic Syndromes 2Esophageal Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Squamous Cell 2Tongue Neoplasms 1Thrombosis 1Thrombocytosis 1Stomach Neoplasms 1Salivary Gland Neoplasms 1Recurrence 1Polycythemia 1Papillomavirus Infections 1

Interventions

Temozolomide 44Radiotherapy 20Magnetic Resonance Spectroscopy 13Irinotecan 13Carboplatin 11Bevacizumab 11Filgrastim 9Surgical Procedures, Operative 7Procarbazine 6sargramostim 5Vincristine 5Imatinib Mesylate 5Etoposide 5Erlotinib Hydrochloride 5Carmustine 5Biopsy 5etoposide phosphate 4Peripheral Blood Stem Cell Transplantation 4Lomustine 4Immunohistochemistry 4Cyclophosphamide 42-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 4temsirolimus 3poly ICLC 3aldesleukin 3Thalidomide 3Surveys and Questionnaires 3Radiation 3Polymerase Chain Reaction 3Gadolinium DTPA 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Oligodendroglioma × Hydroxyurea × Clear all
NCT00387933 2015-10-14

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Duke University

Phase 1 Completed
37 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡